Trial Profile
Phase 0 Trial Evaluating the Effect of Temsirolimus on Known Pharmacodynamic Targets.
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Cancer
- Focus Biomarker; Pharmacodynamics
- 15 Oct 2013 Planned End Date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
- 04 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 11 Apr 2012 Actual patient number 30 added as reported by ClinicalTrials.gov.